SCHEMBL4525700

SCHEMBL4525700

CC(C)(C)OC(=O)N(c1ccc(-c2ccncc2)cc1)[C@H](Cc1ccccc1Cl)C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.39
CYP17A1 P05093 1/20 0.34
CYP51A1 Q16850 1/20 0.34
PAX8 Q06710 1/20 0.34
SLC16A3 O15427 1/20 0.34
SLC16A1 P53985 1/20 0.34
MCTS1 Q9ULC4 1/20 0.34
GPR88 Q9GZN0 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
F2 P00734 1/20 0.33
MGLL Q99685 1/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
CYP19A1 P11511 1/20 0.33
BUB1 O43683 1/20 0.33
NAMPT P43490 1/20 0.33
F10 P00742 1/20 0.33
PRSS1 P07477 1/20 0.33
S1PR1 P21453 1/20 0.32
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512483 0.88 CTSS (0.38) CYP17A1PAX8AAK1F2MGLL
SCHEMBL4517315 0.84 ROCK2 (0.44) CYP17A1SLC16A3ROCK2ROCK1
SCHEMBL4531527 0.83 CDK4 (0.49)
SCHEMBL4525695 0.81 P2RX7 (0.38) P2RX7CYP17A1CYP51A1PAX8GPR88
SCHEMBL4514379 0.80 GRM2 (0.41) CYP17A1AAK1MGLLROCK1
SCHEMBL4527461 0.80 GRM2 (0.41) CYP17A1AAK1MGLLROCK1
SCHEMBL4533235 0.80 CYP17A1 (0.39) CYP17A1AAK1MGLLROCK2ROCK1
SCHEMBL4526796 0.80 KIF11 (0.39) CYP17A1AAK1MGLLROCK2ROCK1
SCHEMBL4519180 0.80 GPR142 (0.41) CYP17A1ROCK2ROCK1CYP19A1
SCHEMBL4524959 0.79 ROCK1 (0.51) MGLLROCK2ROCK1F10PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA P2RX7 4619/4885CYP17A1 3015/4885CYP51A1 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.